Geode Capital Management
OBIO icon

Geode Capital Management’s Orchestra BioMed OBIO Stock Holding History

Geode Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.35M Buy
1,007,908
+522,416
+108% +$2.14M ﹤0.01% 2984
2026
Q1 		$2.06M Buy
485,492
+12,129
+3% +$51.6K ﹤0.01% 3105
2025
Q4 		$1.97M Buy
473,363
+86,564
+22% +$349K ﹤0.01% 3176
2025
Q3 		$960K Buy
386,799
+84,717
+28% +$234K ﹤0.01% 3394
2025
Q2 		$810K Sell
302,082
-293,350
-49% -$856K ﹤0.01% 3398
2025
Q1 		$2.55M Buy
595,432
+22,991
+4% +$114K ﹤0.01% 2948
2024
Q4 		$2.29M Buy
572,441
+5,222
+0.9% +$28K ﹤0.01% 3083
2024
Q3 		$2.92M Buy
567,219
+11,002
+2% +$71.9K ﹤0.01% 3009
2024
Q2 		$4.53M Buy
556,217
+116,119
+26% +$673K ﹤0.01% 2786
2024
Q1 		$2.32M Buy
440,098
+14,349
+3% +$97.2K ﹤0.01% 3058
2023
Q4 		$3.89M Buy
425,749
+10,044
+2% +$68.6K ﹤0.01% 2829
2023
Q3 		$3.63M Buy
415,705
+220,949
+113% +$1.49M ﹤0.01% 2798
2023
Q2 		$1.36M Buy
194,756
+69,750
+56% +$1.06M ﹤0.01% 3239
2023
Q1 		$2.45M Buy
125,006
+112,585
+906% +$1.3M ﹤0.01% 2945
2022
Q4 		$124K Hold
12,421
– – ﹤0.01% 4311
2022
Q3 		$123K Hold
12,421
– – ﹤0.01% 4469
2022
Q2 		$123K Hold
12,421
– – ﹤0.01% 4502
2022
Q1 		$123K Hold
12,421
– – ﹤0.01% 4583
2021
Q4 		$124K Buy
12,421
+2,033
+20% +$20K ﹤0.01% 4654
2021
Q3 		$102K Hold
10,388
– – ﹤0.01% 4669
2021
Q2 		$105K Buy
+10,388
New +$107K ﹤0.01% 4546

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's OBIO Position: Q2 2026 in Review

Geode Capital Management increased its Orchestra BioMed (OBIO) stake by 108% in Q2 2026, buying an estimated $2.14M and bringing the position to 1,007,908 shares worth $4.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

Geode Capital Management first reported a position in OBIO in Q2 2021 and has held it in 21 quarters since. The position peaked at $4.53M in Q2 2024. 72 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Geode Capital Management held 1,007,908 shares of Orchestra BioMed worth $4.35M as of Q2 2026.
  • Geode Capital Management bought 522,416 Orchestra BioMed shares in Q2 2026, an estimated $2.14M.
  • Orchestra BioMed made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2984 holding.
  • Geode Capital Management first reported a position in Orchestra BioMed in Q2 2021 and has held it in 21 quarters since.
  • Geode Capital Management's Orchestra BioMed position peaked at $4.53M in Q2 2024.
  • 72 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.